Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial

BACKGROUND: New anti-tuberculosis regimens that are shorter, simpler, and less toxic than those that are currently available are needed as part of the global effort to address the tuberculosis epidemic. We aimed to investigate the bactericidal activity and safety profile of combinations of bedaquili...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Lancet Respir Med
Main Authors: Tweed, Conor D, Dawson, Rodney, Burger, Divan A, Conradie, Almari, Crook, Angela M, Mendel, Carl M, Conradie, Francesca, Diacon, Andreas H, Ntinginya, Nyanda E, Everitt, Daniel E, Haraka, Frederick, Li, Mengchun, van Niekerk, Christo H, Okwera, Alphonse, Rassool, Mohammed S, Reither, Klaus, Sebe, Modulakgotla A, Staples, Suzanne, Variava, Ebrahim, Spigelman, Melvin
Formato: Artigo
Idioma:Inglês
Publicado: Elsevier 2019
Assuntos:
Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7641992/
https://ncbi.nlm.nih.gov/pubmed/31732485
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2213-2600(19)30366-2
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares